Clinical trials: in Burkina Faso
Malaria Infection
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and…
- Trial name
- NCT05974267
- Testing
- M5717 60 mg, Pyronaridine, Atovaquone-Proguanil
- Where
- 4 sites in Burkina Faso, Kenya and 2 more
- Volunteers
- 192 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Plasmodium Falciparum Malaria
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study was to evaluate PK, safety, tolerability and efficacy of a new formulation of artemether-lumefantrine dispersible tablet in neonates and infants <5 kg body weight with acute uncomplicated Plasmodium…
- Trial name
- CALINA (NCT04300309)
- Testing
- artemether:lumefantrine (2.5 mg:30 mg)
- Where
- 3 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults
The primary objective of the study is to evaluate the safety of 3 different dosages (20µg - 50µg and 100µg) of a placental malaria vaccine candidate (PRIMVAC vaccine) adjuvanted either with Alhydrogel® or GLA-SE, and administered…
- Trial name
- PRIMALVAC (NCT02658253)
- Testing
- PRIMVAC, GLA-SE, Alhydrogel
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Malaria, Falciparum
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite…
- Trial name
- AMA1-DiCo (NCT02014727)
- Testing
- Group A1 : 50µg AMA1-DiCo + Alhydrogel, Group A2 : 50 µg AMA1-DiCo+ GLA-SE
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hiv
HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen
This is a prospective observational study enrolling People Living with HIV (PLHIV) who are on a Dolutegravir-based AntiRetroviral Treatment (ART) regimen and experiencing virologic failure.
- Trial name
- DTG-Resist (NCT06285110)
- Where
- 22 sites in Argentina, Brazil and 14 more
- Volunteers
- 1,103 people
- Sponsor
- University of Bern
Malnutrition, Child, Malnutrition, Infant
Mother Screening for Relapse Using Mid-upper Arm Circumference Among Children Recovered From Severe Acute Malnutrition (Full Scale Trial)
A 1:1:1 individually randomized unmasked controlled trial is proposed in which caregivers will be trained to screen their children who have recovered from an episode of SAM (severe acute malnutrition) using MUAC (mid-upper arm…
- Conditions
- Malnutrition, Child, Malnutrition, Infant, Malnutrition or Risk of Malnutrition, Hemoglobin Level Measurement
- Trial name
- MAMAN (NCT06599580)
- Testing
- Training caregivers to screen children for malnutrition relapse, Reduced follow-up schedule
- Where
- Burkina Faso
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Pregnancy, Malaria, Antepartum
Safety of Antimalarials in the FIRst trimEster
The SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in pregnancy for both mother and baby.
- Conditions
- Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)
- Trial name
- SAFIRE (NCT06962319)
- Testing
- dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 1,510 people
- Sponsor
- Liverpool School of Tropical Medicine
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235020)
- Testing
- INE963
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the…
- Trial name
- DeTACT-Africa (NCT03923725)
- Testing
- Artemether-lumefantrine+ Amodiaquine (AL+AQ), Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Where
- 8 sites in Burkina Faso, Democratic Republic of the Congo and 6 more
- Volunteers
- 2,583 people
- Sponsor
- University of Oxford
Environmental Enteric Dysfunction (EED)
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)
Burden: Environmental Enteric Dysfunction (EED) is an enteropathic condition characterized by altered gut permeability, infiltration of immune cells and changes in villous architecture and cell differentiation.
- Trial name
- MPIGH-II (NCT07134790)
- Testing
- VE818, Oral Vancomycin
- Where
- Burkina Faso
- Volunteers
- 144 people
- Sponsor
- University Ghent
Malnutrition, Child, Severe Acute Malnutrition
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Amoxicillin is recommended by the World Health Organization (WHO) as adjunctive therapy for the treatment of uncomplicated severe acute malnutrition (SAM).
- Trial name
- AMOUR (NCT06010719)
- Testing
- Azithromycin, Amoxicillin
- Where
- Burkina Faso
- Volunteers
- 3,000 people
- Sponsor
- University of California, San Francisco
Pediatric Cancer
Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group.
- Trial name
- RFAOP (NCT03803735)
- Where
- 14 sites in Burkina Faso, Cameroon and 10 more
- Volunteers
- 10,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Antimicrobial Stewardship, Drug Resistance, Bacterial
Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo
Emergence of antibiotic resistance (AMR) is a serious concern for Low and Middle Income Countries (LMICs). Unregulated use of antibiotics, a major AMR driver, is highly prevalent in LMICs, with medicine stores as key providers.
- Trial name
- CABU-B/C (NCT05378880)
- Testing
- Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission
- Where
- 2 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 5,532 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Cervical Cancer
SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)
The goal is to assess the feasibility and acceptability of integrating into existing health systems, provision of HPV screening and treatment of pre-cancerous cervical cancer lesions with ablative treatments in Burkina Faso, Côte…
- Trial name
- HPV (NCT05133661)
- Testing
- HPV testing
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 17,602 people, healthy volunteers welcome
- Sponsor
- Jhpiego
Neonatal Death, Infectious Disease
Vitality in Infants Via Azithromycin for Neonates Trial
Nearly half of child deaths occur during the neonatal period, and 80% of those occur in babies with low birthweight. Although tremendous progress has been made towards reducing under-five mortality globally, declines in neonatal…
- Conditions
- Neonatal Death, Infectious Disease, Nutritional Deficiency
- Trial name
- VIVANT (NCT05763693)
- Testing
- Azithromycin at Baseline, Azithromycin at Day 21
- Where
- Burkina Faso
- Volunteers
- 4,000 people
- Sponsor
- University of California, San Francisco
Acute Malaria
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
- Trial name
- NCT05689047
- Testing
- M5717 330 mg, M5717 500 mg, M5717 660 mg
- Where
- 5 sites in Burkina Faso, Gabon and 2 more
- Volunteers
- 38 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Malaria,Falciparum, Morality
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are…
- Trial name
- NCT07009847
- Testing
- Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
- Where
- 5 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 2,308 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria Vaccine
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21…
- Trial name
- IMVACS (NCT06860178)
- Testing
- Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Pregnancy Related
Evaluation of Electronic Pregnancy Registers and Mobile Applications for Monitoring Pregnancy Outcomes ( EVAPREAP )
Monitoring pregnancy outcomes during pregnancy is very important in assessing the effectiveness of interventions. This study aims to create pregnancy registers and evaluate pregnancy mobile applications as a potential tool for…
- Trial name
- NCT06225739
- Testing
- Electronic pregnancy register, In-depth interviews and focus group discussions
- Where
- 4 sites in Benin, Burkina Faso and 2 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals